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Abstract
The induction of sterilizing T-cell responses to tumors is a major goal in the development of T-cell vaccines for treating
cancer. Although specific components of anti-viral CD8+ immunity are well characterized, we still lack the ability to mimic
viral CD8+ T-cell responses in therapeutic settings for treating cancers. Infection with the picornavirus Theiler’s murine
encephalomyelitis virus (TMEV) induces a strong sterilizing CD8+ T-cell response. In the absence of sterilizing immunity, the
virus causes a persistent infection. We capitalized on the ability of TMEV to induce strong cellular immunity even under
conditions of immune deficiency by modifying the virus to evaluate its potential as a T-cell vaccine. The introduction of
defined CD8+ T-cell epitopes into the leader sequence of the TMEV genome generates an attenuated vaccine strain that can
efficiently drive CD8+ T-cell responses to the targeted antigen. This virus activates T-cells in a manner that is capable of
inducing targeted tissue damage and glucose dysregulation in an adoptive T-cell transfer model of diabetes mellitus. As a
therapeutic vaccine for the treatment of established melanoma, epitope-modified TMEV can induce strong cytotoxic T-cell
responses and promote infiltration of the T-cells into established tumors, ultimately leading to a delay in tumor growth and
improved survival of vaccinated animals. We propose that epitope-modified TMEV is an excellent candidate for further
development as a human T-cell vaccine for use in immunotherapy.
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Introduction
Theiler’s murine encephalomyelitis virus (TMEV) is a natural
mouse pathogen that has been used to identify the T-cell effector
molecules necessary for clearance of central nervous system
infection. These findings show that viral clearance depends on
CD8+ a/b T-cell interactions with viral peptides presented in the
context of specific MHC class I alleles [1,2], with the best example
being the response to VP2121–130 in the context of H-2D
b [3,4].
Further, these strong T-cell responses can be elicited in the absence
of CD4+ T-cells, CD28 co-stimulation and interferon gamma [5].
The ability to drive strong CD8 T-cell immunity in a variety of
immune deficient states makes TMEV an attractive vaccine vector
for eliciting CD8 T-cell responses to tumor antigens. Previous work
has shown that the introduction of fluorescent proteins into the
genome of TMEV can be used as a tool to track cells infected with
thisvirusanddisruptionoftheviralgenomedoesnotblockitsability
to infect cells [6]. Further, the introduction of MHC class II
restricted self antigens into the virus has been used as a way to
enhance the autoimmune attack incurred through infection of the
central nervous system with recombinant TMEV [7]. The current
work examines the ability of a modified TMEV vaccine to direct
robust systemic CD8-restricted anti-tumor immunity to introduced
antigens.
The ideal viral vaccine has not yet been established. Several
viruses have been adapted as potential carriers of antigen for
elicitingtargeted anti-tumorimmunity [8,9].However, theseviruses
are often composed of large genomes whose constituents are often
used to avoid immune detection [10,11]. We have introduced the
MHCclass I model peptide OVA257into thecoding sequenceofthe
8093 base pair genome of TMEV (TMEV-L/OVA) for use as a
potential anti-tumor vaccine. Despite some attenuation due to
genetic modification, this relatively small virus can efficiently
generate CD8+ cytotoxic T-cell responses to the introduced antigen
and inhibit tumor growth through the specific induction of tumor
infiltrating lymphocytes. This new virus vaccine provides a model
for studying the requirements needed for immune mediated
destruction of tumor cells and gives us the opportunity to dissect
the important aspects of T-cell, tumor and host biology and their
contributions to effective anti-tumor responses. Furthermore,
TMEV is easy to grow and is not known to be a human pathogen
despite being used extensively in the scientific community. This
makes TMEV an interesting candidate for further development as
an effective, safe and inexpensive vaccination for immunotherapy.
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Ethics Statement
This study was carried out in accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health and according to the
Institutional Animal Care and Use Committee of Mayo Clinic.
These studies were specifically approved by IACUC under
protocols A38409 and A43310.
Mice
C57BL/6, C57BL/6-Tg(Ins2-OVA)59Wehi/WehiJ(RIP-OVA )
and C57BL/6-Tg(TcraTcrb)1100Mjb/J (OT-1) mice were
obtained from Jackson Laboratory (Bar Harbor, ME) and
maintained in the institutional animal facility. H-2D
bm14 (bm14)
[12] were bred and maintained in the same facility. All animals
were housed and cared for according to institutional and NIH
guidelines for animal care and use. Animals were euthanized
when tumor sizes exceeded 225 mm
2.
Cell lines
B16, L929 and BHK cells were maintained in DMEM (GIBCO
Invitrogen, Grand Island, NY) and EL4 were maintained in RPMI
(GIBCO/Invitrogen) containing 10% Cosmic
TM calf serum
(Hyclone, Logan, UT). B16-OVA lines were maintained in the
same media supplemented with 10 mg/mL Geneticin (GIBCO
Invitrogen, Grand Island, NY).
Reagents
PerCP labeled anti-mouse CD45 and FITC labeled anti-mouse
CD8 were purchased from BD Biosciences (San Diego, CA, USA).
PE labeled H-2K
b/OVA257 tetramers (part no. T03000) were
purchased from Beckman Coulter (Brea, CA, USA). PE labeled H-
2D
b/VP2121 tetramers were kindly provided by the NIH
Tetramer Core at Emory University (Atlanta, GA, USA).
VP2121 (FHAGSLLVFM), OVA257 (SIINFEKL) and E749
(RAHYNIVTF) peptides were synthesized by Elim Biopharm
(Hayward, CA, USA).
Vaccine generation and quantification
Epitope modified vaccine was generated from a cDNA clone of
the Daniel’s strain of TMEV, pDAFL3 [13]. Two epitopes including
the H-2D
b epitope gp33 from LCMV and the H-2K
b epitope
OVA257 were introduced into an Xho I restriction site within the
leader sequence of TMEV. The two epitope fragments were
amplified independently and then linked through PCR splicing by
overlap extension [14], digested with Xho I and ligated into the
leader sequence at position 1221 of the TMEV genome. As
described previously [13], T7 RNA transcripts were generated and
transfected into BHK cells using electroporation. Five days later
supernatant and cells were harvested and assayed for the presence of
virus using plaque assays on L929 cells. Once viral titers were
determined, high titer virus for injection was generated by
inoculating flasks of BHK at an MOI of 0.01 [15]. Final virus titers
were determined by plaque assay. Mice were inoculated with either
5610
5 PFU intracranially or with 5610
6 PFU intraperitoneally.
Brains and spinal cord from mice infected with TMEV-wt or
TMEV-L/OVA for 6 days were homogenized, sonicated and
clarified. Homogenates were tested for viral titer using plaque
assays described previously [16].
The 7900HT Fast Real-Time PCR System (Applied Biosys-
tems, Carlsbad, CA, USA) was used to quantify viral RNA in 24
day infected brain and spinal cord homogenates from mice
inoculated with TMEV-wt or TMEV-L/OVA. RNA was isolated
using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) and
reverse transcribed using the Superscript cDNA synthesis kit
(Invitrogen). Reaction was set up using the Fast SyBR Green
Master Mix Kit (Applied Biosystems). cDNA was amplified using
primers specific for mouse actin (F – 59CTGGCACCACACCT
TCTACAATGAGCTG and R– 59GCACAGCTTCTCTTTGA
TGTCACGCACGATTTC) and for viral protein 2 (VP2) of
TMEV (F-59TGGTCGACTCTGTGGTTACG and R-59 GCC
GGTCTTGCAAAGATAGT). Cycling conditions were as fol-
lows: 50uC for 2 minutes, 95uC for 10 minutes followed by 40
cycles of 95uC at 15 seconds then 55uC for 1 minute. Amplifica-
tion curves and crossing point thresholds were based on SYBR
Green incorporation. Samples were normalized to actin and data
are reported as fold increase over background.
In vivo and in vitro killing assay
Chromium release assays were used to determine cytotoxic cell
killing from brain infiltrating and tumor infiltrating lymphocytes.
For mice intracranially infected with virus, brains were recovered
from 6 day TMEV infected mice and brain infiltrating
lymphocytes (BIL) were isolated via percoll gradient as described
previously [5]. Tumor infiltrating lymphocytes (TIL) were
recovered by removing implanted tumors and physically disrupt-
ing the tumor before passing through a 45 mm cell strainer. To
enrich for lymphocytes, disrupted tumor cells were allowed to
settle for 15 minutes before harvesting lymphocytes. Peptide
pulsed and unpulsed EL4 cells were used as targets in a standard
4 hour chromium release assay.
In vivo killing assays were used to assess target cell specific
killing after induction of cytotoxic T-cells [17]. Briefly, we labeled
3 target populations of splenocytes with high concentration
carboxyfluorescein succinimidyl ester (CFSE), low concentration
CFSE and with a third label PKH26 (Sigma-Aldrich, St. Louis,
MO, USA). These three populations were labeled with OVA257,
E749 or VP2121 before intravenous injection into TMEV
vaccinated mice. Splenocytes were harvested and individually
analyzed by flow cytometry to determine the percent killing of
individual populations of labeled cells. Percent killing was
normalized to the irrelevant peptide control population pulsed
with E749 peptide.
RIP-OVA model of diabetes mellitus
RIP-OVA mice received 5610
6 PFU of TMEV-wt or TMEV-
L/OVA vaccine on the same day as adoptive transfer of OT-1
CD8+ cells or without transfer. Mice receiving intravenous
transfer were given 1610
7 purified CD8+ T-cells enriched with
the mouse CD8a+ T-cell isolation kit (Miltenyi Biotec, Bergisch
Gladbach, Germany). Glucose levels were monitored daily using a
Lifetouch glucomoter (Lifescan, Milpitas, CA U.S.A). After two
successive readings of .500 mg/dL, mice were sacrificed for
histologic analysis and insulin immunohistochemistry. Pancreata
were harvested and fixed in formalin before paraffin embedding
and sectioning. Sections were stained with hemotoxylin and eosin
using standard procedures. Microscopic analysis and imaging was
performed on an Olympus DP70 camera attached to an Olympus
AX70 research microscope (Olympus America Inc., Center
Valley, PA).
Tumor growth, recovery and analysis
B6 mice were challenged in the right flank with 5610
5 B16 or
B16-OVA tumor cells and were treated with viral vaccines on the
day of tumor challenge or on day 9 after challenge. Tumors were
measured in two dimensions every other day. Tumor index is
reported as the square root of the product of both dimensions
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recovered and disrupted with the plunger from a 3 mL syringe,
then passed through a nylon mesh filter. An aliquot of cells was
used to isolate RNA using the RNEasy kit (Qiagen, Germantown,
MD) to determine expression of the transfected ovalbumin gene by
qRT-PCR. Cells were plated in 12 well plates at 2610
5 cells per
well in media supplemented with or without G418 (Invitrogen).
Three days later, cells were washed, fixed and stained with crystal
violet. Plates were scanned with a flat bead scanner and percent of
area covered by crystal violet stained cells was determined using
ImageJ (National Institutes of Health; http://rsbweb.nih.gov/ij/
index.html).
Statistics
Statistical analysis was performed using SigmaStat3.1 software
(Systat Software, San Jose, CA). Non-parametric ordinal data were
analyzed by rank-sum test and categorical data by Fisher Exact
test. Normally distributed data were analyzed by student’s t-test or
by one-way or two-way ANOVA with pairwise comparisons done
by Student-Neuman-Keuls Method. Significance was determined
by P values less than 0.05.
Results
Epitope modified TMEV replicates in vitro but does not
manifest a persistent infection
We sought to use TMEV as a vector for driving an immune
response against introduced epitopes. Based on previous observa-
tions that introduction of epitopes within a Xho I restriction site
(Figure 1A) in the leader sequence could be used as a vector for
foreign gene delivery, we engineered the pDAFL3 clone [13] to
encode two model epitopes in the leader sequence of the TMEV
clone. Two model epitopes, the H-2D
b epitope gp33 from LCMV
and the H-2K
b epitope OVA257 from ovalbumin (Figure 1B) were
introduced into the TMEV genome, positive stranded RNA was
generated and transfected into BHK cells to generate epitope
modified TMEV-L/OVA virions.
To verify that the modified virus was viable and infectious we
performed plaque assays on transfected BHK supernatants to
determine viral titers. The TMEV-L/OVA was raised to a titer
4610
5/ml supernatant as compared to 2610
7 for wild-type virus,
suggesting a possible loss in virulence. The size of individual
plaques generated by the TMEV-L/OVA virus was notably
reduced compared to a cultured passage of wild-type TMEV-
DAV (Figure 1C). Since intracranial infection is often used to
determine virulence of TMEV, we injected viruses into the brains
of C57BL/6 mice and determined the titer of TMEV-wt and
TMEV-L/OVA by plaque assay from brain and spinal cord
homogenates after six days of infection. The viral titers TMEV-L/
OVA maintained in the CNS after 6 days of infection were
significantly reduced compared to TMEV-wt (Figure 1D). The
Daniel’s strain of TMEV can persist in the CNS of genetically
susceptible hosts [2]. To determine whether our modified virus
would persist, we infected resistant C57BL/6 or susceptible FVB
mice for 21 days. As expected, infection of the resistant strain with
TMEV-L/OVA did not lead to persistence as demonstrated by
the lack of viral specific transcripts. Further, the modified virus did
not persist in the susceptible FVB strain either (Figure 1D). In
comparison, FVB infected with TMEV-wt maintained TMEV
transcripts at a level that was 30,000 fold higher than background.
This demonstrates that while TMEV-L/OVA is still infectious, its
inability to persist in susceptible hosts and its reduced virulence
show that the virus is substantially attenuated.
Generation of CD8+ effectors against epitopes
introduced into the TMEV genome
Since we have shown that the epitope modified TMEV is still
competent in its ability to infect cells, we next determined whether
this virus could generate CD8+ effector cells against the introduced
epitopes. Intracranial injection of TMEV-wt into C57BL/6 mice
leads to an immunodominant CD8+ effector cell population that is
specific for the H-2D
b specific viral epitope VP2121 [5]. Although
not intended as a route of therapy, intracranial (ic) infection
provides a convenient way to monitor the induction of tissue
infiltrating inflammatory cells. Our engineered virus contains
epitopes for the H-2D
b restricted epitope gp33 and the H-2K
b
epitope OVA257. We infected mice ic with TMEV-L/OVA and
evaluated the CNS infiltrating CD8+ T-cell population by using
tetramers specific for gp33, OVA257 and VP2121. CD8+ cells
staining with K
b:OVA257 tetramer, as well as cells staining with the
VP2121:D
b tetramer were detected readily (Figure 2A).
The coincidence of two immunodominant responses against
peptide epitopes encoded in the virus genome raised the question
of whether competition among epitopes included in the vaccine
could alter immunization efficiency. In a previous study, we
demonstrated that the H-2D
b mutant bm14 is unable to mount a
response to the VP2121 epitope due to changes in antigen
presentation by the bm14 molecule [18]. We used this model
system to determine whether responses to the H-2K
b allele would
be enhanced in the absence of a response to the D
b restricted
virus-encoded VP2121 epitope. Similar to previous findings with
TMEV-wt (26), there was no CD8+ T-cell response to VP2121 by
the bm14 mice challenged with TMEV-L/OVA. However, the
response to the ovalbumin epitope represented a greater
proportion of the CD8+ T-cells present in the brains of bm14
mice infected with TMEV-L/OVA for 6 days (48% of the CD8 T
cells) compared to infection of wild-type mice (18% of the CD8 T
cells). Assuming that the CD8+ T cell responses to epitopes
encoded by TMEV-L/OVA virus by B6 wildtype mice are
independent (i.e. 39.3% anti-VP2, 18.3% anti-OVA, and 42.4%
undefined), deletion of the VP2 specific response would have been
expected to result in 30% of the remaining CD8+ T cells having
OVA specificity (18.35/[18.35+42.4%]), not the observed 48%.
Therefore, it seems likely that the presence of more than one
immunodominant epitope in a virus might result in competition,
influencing the effectiveness of the vaccine against individual
epitopes of interest. This important point will need further
investigation, as immunization against multiple epitopes is a
frequent goal of designs of T cell vaccines.
Having demonstrated that CD8+ cells can be elicited specific for
an introduced peptide epitope with our modified virus, we next
tested whether this response was effective at generating cytotoxic
effectors. To address this, we harvested lymphocytes from the
CNS of mice intracranially infected with TMEV-wt or with
TMEV-L/OVA and tested their ability to lyse chromium labeled
target cells. As shown previously, lymphocytes harvested directly
from TMEV-wt infected CNS kill VP2121 peptide pulsed targets
very effectively (Figure 2B). Similarly, the epitope modified virus
was able to elicit cytotoxic lymphocytes that could target directly
both the dominant viral epitope and the introduced ovalbumin
epitope, demonstrating the virus’ effectiveness at driving cytotoxic
effector cell responses to introduced antigens.
Since we were able to demonstrate effective killing by CNS
infiltrating lymphocytes directly ex vivo, we wanted to determine
whether an intraperitoneal injection of TMEV-L/OVA could
generate effective killing in vivo. We injected TMEV-wt and
TMEV-L/OVA viruses directly into the peritoneum and on day
six challenged the mice with peptide pulsed splenocytes to
TMEV as a Vaccine Candidate
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targets. Consistent with the chromium release assay, TMEV-wt
vaccinated mice generated robust responses against VP2121,
whereas the TMEV-L/OVA vaccinated mice killed both VP2121
and OVA257 pulsed targets. These data indicate that the epitope
modified vaccine can elicit effector cells against introduced
antigens and that these responses can effectively clear target cells
presenting the targeted antigens in vivo. Administration of the
virus via intracranial, intraperitoneal or intravenous route yielded
comparable results (data not shown).
Targeted tissue damage induced in vivo with modified
TMEV vaccine
Having established that epitope modified TMEV can elicit
CD8+ T-cell specific immunity, we asked whether systemic
vaccination could activate cytotoxic effectors that could infiltrate
and destroy antigen bearing cells in solid tissues. We used adoptive
transfer of OT-1 T-cells into RIP-OVA mice as a model,
visualizing cellular immune attack against beta cells in the
pancreas. In the absence of OT-1 transferred T-cells, RIP-OVA
mice injected with either TMEV-wt or with TMEV-L/OVA
Figure 1. The generation of epitope modified TMEV vaccine. (A) The genome of TMEV contains an Xho I restriction site within the leader
sequence which can be used for insertion of MHC class I peptide epitopes. (B) Sequence of LCMV and ovalbumin linked epitopes inserted into the
Xho I restriction site of the pDAFL3 vector. (C) Productive infection and plaques from wild-type and modified TMEV virus. (D) Plaque assay (left) of
virus recovered from the brains of mice infected with virus for 6 days (*p=0.014). Absence of detectable viral transcripts in the brain 21 days after
inoculation with TMEV-L/OVA vaccine in B6 and FVB mice (right).
doi:10.1371/journal.pone.0020217.g001
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into pancreatic islets (Figure 3A and B). TMEV-L/OVA
vaccination of RIP-OVA mice reconstituted with OT-1 T-cells
generated robust pancreatic islet inflammation (Figure 3C),
whereas TMEV-wt vaccination had no effect (Figure 3D). The
ability of the infiltrating T cells to damage the islets was evident as
the mice receiving both OT-1 transfer and TMEV-L/OVA
vaccination developed high glucose levels, characteristic of type 1
diabetes. We conclude from this study that TMEV-L/OVA
vaccination activates CD8+ T-cells which can specifically target
and damage antigen expressing tissues.
Epitope modified TMEV vaccine edits ovalbumin
expressing tumors and inhibits B16-OVA outgrowth
Since we were able to effectively activate OT-1 cells in vivo
using the TMEV-L/OVA virus, we asked whether we could
activate a polyclonal T-cell response in the absence of non-
transgenic T-cells using the native repertoire in B6 mice. We used
the melanoma tumor model B16-OVA to determine whether the
epitope modified vaccine could effectively target the tumor and
inhibit outgrowth. Since oncolytic viral therapy is often used to
directly target and kill tumor cells, we first asked whether TMEV
or our modified virus could directly target and kill the B16
melanoma line, which does not express the ovalbumin epitope,
OVA257, or the viral epitope VP2121. We challenged B6 mice with
the B16 tumor line in the flank of the hind leg and then vaccinated
them ip with either the TMEV-wt or TMEV-L/OVA viruses.
Neither virus was able to inhibit tumor outgrowth (Figure 4A),
which proceeded comparably to tumor growth we have observed
repeatedly in mice not receiving virus challenge (data not shown).
We then asked whether these viruses could be used to elicit
tumor specific immunity against the B16-OVA tumor line. Mice
were challenged with B16-OVA on the same day as vaccination
with the wild-type and epitope modified virus. By day 14 all of the
TMEV-wt treated mice had measurable tumors, whereas only one
mouse in the TMEV-L/OVA treated group had a measurable
tumor (Figure 4B). The durability of the tumor inhibition varied
substantially among the mice treated with the TMEV-L/OVA
virus, raising the possibility that a stochastic event was contributing
to resistance to the tumor or tumor escape. To determine whether
tumors were avoiding sterilization by escaping immune selection,
we analyzed tumors that grew out of TMEV-wt and TMEV-L/
OVA immunized mice. The B16-OVA tumor was prepared
originally by introduction of transgenes expressing chicken
ovalbumin and a neomycin resistance gene from E. coli transposon
Tn5. By growing single cell suspensions of harvested tumors and
assessing them for resistance to G418, the presence of the
antibiotic resistance gene co-expressed on the ovalbumin construct
used to generate the B16-OVA tumor cell line was assessed. We
found that mice treated with the TMEV-wt virus primarily grew
tumors that were resistant to G418, consistent with the presence of
the ovalbumin vector. However, the tumors from TMEV-L/OVA
vaccinated animals had a dramatic reduction in their resistance to
G418 (Figure 4C). Finally, semi-quantitative RT-PCR analysis of
tumor cells demonstrated that there was a significant reduction in
expression of ovalbumin specific transcripts in the TMEV-L/OVA
treated mice. These data indicate that the virus vaccine induces
effective immunity primarily targeting ovalbumin expressing cells
and that immune editing has allowed tumors which have lost
expression of the transgene containing both the OVA antigen and
neomycin resistance to predominate. This form of immune editing
of the B16-OVA tumor was demonstrated initially using OVA
specific OT-1 T cells by our colleagues, Karen Kaluza and
Richard Vile, Mayo Clinic (personal communication and
manuscript in preparation).
Treatment of 9 day established B16-OVA tumors with
epitope modified TMEV leads to robust tumor specific
immunity, enhanced antigen specific tumor infiltrating
lymphocytes and delays tumor outgrowth
Because we found that TMEV-L/OVA vaccination has an
effect on B16-OVA outgrowth when tumor was given at the time
of virus challenge, we wanted to determine whether this treatment
could be effective in an established tumor model. We challenged
mice with B16-OVA in the flank of the hind leg nine days prior to
infection with TMEV-wt or TMEV-L/OVA virus and monitored
the immune response to the OVA257 and VP2121 epitopes.
Although systemic infection with the TMEV vaccine induced
robust CTL, in these experiments we introduced this virus
intracranially to facilitate monitoring the recruitment and
Figure 3. Induction of diabetes with TMEV-L/OVA using RIP-OVA mice given OT-1 T-cell transfer. Representative pancreatic islets from
RIP-OVA mice given TMEV-wt (A) or TMEV-L/OVA (B) without OT-1 transfer. (C) Pancreatic islet infiltration observed in OT-1 transferred RIP-OVA
receiving TMEV-L/OVA vaccine compared to TMEV-wt vaccine (D). (E) Blood glucose levels observed in RIP-OVA mice given TMEV-wt or TMEV-L/OVA
vaccines. Increased blood glucose was observed on day 6 (p=0.007), 7 (p,0.001), 8 (p,0.001) and 9 (p,0.001) in mice receiving both OT-1 transfer
and TMEV-L/OVA vaccine compared to transfer with TMEV-wt.
doi:10.1371/journal.pone.0020217.g003
Figure 2. Generation of epitope specific CD8+ T-cell responses with TMEV-L/OVA. (A) FACS analysis of brain infiltrating lymphocytes (BIL)
from mice infected with TMEV-L/OVA for 6 days. The proportion of OVA257 specific T-cells increases in the absence of viral specific CD8+ T-cells
(p,0.001). (B) In vitro cytotoxic activity of BIL as measured by a 4 hour chromium release assay using VP2121 and OVA257 peptide pulsed targets. (C)
OVA257 specific in vivo killing of labeled target cells in 6 day TMEV-L/OVA infected mice was increased compared to TMEV-wt (p=,0.001).
doi:10.1371/journal.pone.0020217.g002
TMEV as a Vaccine Candidate
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e20217TMEV as a Vaccine Candidate
PLoS ONE | www.plosone.org 7 May 2011 | Volume 6 | Issue 5 | e20217migration of viral specific and ovalbumin specific CD8+ T-cells
into the site of infection. Tetramer analysis demonstrated a robust
OVA257 specific infiltration in the brain of infected mice, which
was dramatically reduced in the TMEV-wt mice. Both viruses
elicited VP2121 specific CD8 cells compared to irrelevant E7
tetramer, however the TMEV-L/OVA response to the VP2121
epitope was reduced (Figure 5A), indicating that the TMEV-L/
OVA response focused on the ovalbumin epitope in mice bearing
nine day tumors expressing this antigen.
Since this vaccine generated strong CD8 immunity at the site of
infection, we wanted to determine whether vaccination with
TMEV-L/OVA also altered the quality of the tumor infiltrating
lymphocyte response in established B16-OVA melanomas. Thirty-
five percent of the CD8+ tumor infiltrating T cells stained brightly
with OVA257:K
b tetramer B16-OVA tumor, indicating that the
epitope-modified vaccine delivered at a remote site can influence
the quality of the T-cell response at the tumor. VP2121- specific T-
cells were found in the tumor and none of the tumor infiltrating T
cells stained with the irrelevant E7 tetramer (Figure 5B),
demonstrating the specificity of T-cell infiltration and retention
in the tumor.
One hallmark of effective tumor therapy is the development of
cytotoxic lymphocyte responses specific to the tumor. We
challenged mice bearing 9 day tumors with TMEV-wt or
TMEV-L/OVA ip and assessed the tumor infiltrating lymphocyte
(TIL) population for its ability to kill OVA257 peptide pulsed
targets 6 days after intraperitoneal challenge with either virus. We
found that TIL harvested from the TMEV-L/OVA treated mice
generated effector cells that could effectively target and kill
OVA257 peptide pulsed targets, whereas TMEV-wt treatment
failed to induce this response (Figure 5C).
Because we have established that tumor specific cytotoxic cells
were infiltrating the tumor, we wanted to assess whether this could
influence tumor outgrowth. We monitored tumor outgrowth in
mice seeded with B16-OVA 9 days prior to treatment with either
virus. Twelve and 14 days after a single inoculation of TMEV-L/
OVA virus ip, we observed a significant reduction in tumor size
(65% reduction) compared to the tumors in mice treated with the
wild type virus (Figure 5D). Further, this delay in outgrowth
significantly increased the survival of the TMEV-L/OVA group at
30 days post tumor challenge (Figure 5D), where 7 of 10 animals
had not developed tumors exceeding 225 mm
2 (length, width)
compared to only 2 of 9 mice in the TMEV-wt treated group. This
reduction in tumor burden and delay in outgrowth indicates that
the epitope-modified vaccine can be used to induce immunother-
apeutic responses against established tumors, raising the possibility
of relevance for further development as a candidate vaccine for
treatment of human disease.
Discussion
Successful active immunotherapy strategies will have to
overcome a number of factors limiting effective immune responses
in cancer patients, including immune suppressive tumor micro-
environments, limitations in the immune repertoire resulting from
mechanisms of tolerance, and the need to activate strong immune
responses in vivo. Here we address one of these, the requirement
to activate robust cellular immunity against cancer associated
antigens. We pursued the hypothesis that directing potent anti-
viral immunity against tumors results in sterilizing immunity as we
evaluated the picornavirus, TMEV as a candidate for cancer
vaccine development.
Several characteristics of TMEV make this virus an attractive
candidate as a vaccine vector for immunotherapy. One property
that makes it particularly attractive is that it is not a natural human
pathogen [19]. Although cardioviruses were thought to be
exclusively infective in rodents, a recently identified virus species
in humans shows that asymptomatic infections with the cardio-
virus member Saffold virus are highly prevalent in humans [20].
Furthermore, the precise receptor for TMEV has not been
determined [21], and this virus can infect human cells in vitro
indicating that binding to a conserved receptor could cause a
subclinical infection in humans. This leaves open the possibility
that strong T-cell responses to introduced antigens could be
induced with a TMEV vaccine.
Another attractive property is the relatively small genome that
canbe easily manipulated.One of the drawbacks to the use of larger
viral vectors for vaccine development [22] is that the human
immune system may focus on several viral epitopes rather than
introduced epitopes. TMEV is composed of only 12 unique protein
antigens and infection of resistant C57BL/6 mice leads to T-cell
responses that result in up to 70% of activated CD8+ T-cells
focusing on one major epitope [5]. Simple modifications of this
epitope [23] may subvert CD8 responses against the virus allowing
the immune system to focus on the introduced targets of interest.
This has important implications as we find that responses against
immunodominant epitopes encoded in the vaccine can compete
with each other. Future studies aimed at eliminating potential viral
epitopes recognized by human MHC restricted T-cells could tailor
the virus for effective targeting of antigens of interest. Further, the
predominant antibody neutralization sites for TMEV have been
identified [24], providing approaches for controlling virus infectiv-
ity. Because blocking antibodies are highly effective in preventing
TMEV infection, passive transfer of antibody could help control
virus infection and elimination of antibody epitopes could enhance
ability to revaccinate and give rise to increased cellular immunity.
Our studies demonstrate that the introduction of a single
epitope can have a significant effect on tumor outgrowth and
survival; however tumors in most mice did continue to grow and
demonstrated immune editing as shown by a decrease in
ovalbumen expression in vaccine treated animals. It is known
that tumors can use several mechanisms to avoid the immune
response including down-regulation of target antigens [25].
Therefore, the most effective vaccines will be those which can
incorporate multiple antigens including those that are critical to
tumor survival. Prior studies have shown that the 239 amino acid
protein enhanced green fluorescent protein can be introduced into
the genome of TMEV and that infectious virions can be generated
that express this protein [6]. This demonstrates the potential for
this vaccine to be enhanced by driving T-cell responses to multiple
peptide antigens, increasing its effectiveness as a vaccine.
Figure 4. MHC class I epitope specific protection and targeting of B16-OVA melanoma. (A) Vaccination with TMEV-wt or TMEV-L/OVA
virus did not delay tumor outgrowth using the parental B16 tumor model. (B), Tumor outgrowth in mice challenged with B16-OVA tumor and
vaccinated with TMEV-wt (top) or with TMEV-L/OVA (bottom). Tumor sizes were significantly different in these treatment groups on days 10 through
19 (* designates p,0.05). (C) G418 resistance and growth of tumor cells recovered from mice vaccinated with TMEV-wt or with TMEV-L/OVA (left).
Quantitation of cresyl violet stained tumor cells recovered from vaccinated mice. Data expressed as the percent of well area containing stained tumor
cells from TMEV-wt and TMEV-L/OVA vaccine treated mice (middle) (p,0.05). RNA isolated from recovered tumors was analyzed by qRT-PCR for the
presence of ovalbumin specific transcripts (p=0.009).
doi:10.1371/journal.pone.0020217.g004
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PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e20217One concern with modifying viruses for use as vectors is the
possibility that the modified virus may have increased virulence in
the host. Our study demonstrates that modifications we have
introduced have the opposite affect. Several virulence factors in
the capsid and non-capsid regions of the TMEV genome have
been previously identified [26,27,28], including the leader peptide
[29]. We have introduced the H-2K
b restricted epitope OVA257
into the leader sequence of TMEV at position 53 of this 76 amino
acid protein. This non-capsid viral protein has been shown to be
important for inhibiting type I interferon responses that are
important for innate immune responses to the virus as well as for
viral assembly in L cells [30,31]. Since productive virus can be
generated in BHK cells and viruses generate plaques on L cells, it
is unlikely that this insertion affects the function of the leader
sequence in viral assembly. However, this insertion may interfere
with its role in inhibition of type I interferon induction potentially
through its interaction with IRF3 [32] which may explain the
attenuated phenotype observed with the TMEV-L/OVA virus.
Future experiments that address the function of the epitope
modified leader sequence will clarify the role of this disruption in
inhibiting the type I interferon response.
Another concern with using modified virus vaccines is the
potential for recombination between species within the picorna-
virus family which could potentially lead to a more virulent species
[33]. The rodent viruses TMEV and encephalomyocarditis virus
were the only known members of the cardiovirus genus until the
discovery of Saffold virus in 2007 [34], leaving open the possibility
that novel TMEV like viruses may serve as potential genetic
donors for modified TMEV vaccines. However, recombination
within the picornavirus family appears to be limited to viruses
within a species and intra-species recombination is very rare [35].
Most picornavirus infections are asymptomatic however if isolated
only 5% of viral isolates can be expected to contain two or more
strains [33], making the possibility of recombination between an
unknown cardiovirus very unlikely and strengthening the practical
use of TMEV as a vaccine vector.
One important aspect that is implicit in vaccine design is that
the immune response elicited is mechanistically appropriate to the
intended target. Previous work with TMEV has demonstrated that
it is a very strong activator of cytotoxic T-cell responses [36] and
cytotoxicity is dependent on perforin contained in CD8+ T-cells
[37]. The mechanism of killing induced with perforin and
granzymes leads to apoptosis and clearance of targeted cells, a
mechanism favored by investigators designing immune therapies
for the treatment of cancer. The current work demonstrates that
cytotoxic T-cells can be induced to T-cell epitopes that are
artificially introduced into the viral genome. Although infection
with TMEV-L/OVA is a potent inducer of virus specific cytotoxic
T-cell responses at the site of infection, tumor specific T-cells also
invade the tumor at distant sites further strengthening its potential
use as a vaccine vector.
Our findings show that TMEV-L/OVA treatment inhibits
tumor growth and also increases the proportion of tumor specific
lymphocytes in the tumor and in the brain after intracranial
injection of tumor bearing mice. Although we did not make
discreet measurements of the absolute number of OVA257 specific
CD8+ T-cells in the brain after TMEV-L/OVA treatment, our
data show that there was an increase in the quantity and density of
antigen specific T-cells inside the tumor, a more promising
indicator of a positive therapeutic effect [38]. Our methods for
isolating lymphocytes included an enrichment step for brain
infiltrating lymphocytes only. We analyzed a fixed number of
events from the lymphocyte enriched brain homogenate and
found that a higher proportion of T-cells were OVA257 specific
after TMEV-L/OVA treatment, however since the competing
VP2121 response in the wild-type DA and L-OVA infected mice
were not normalized by using a given volume, it is difficult to
determine whether absolute numbers CD8+ brain infiltrating T-
cells were different. However, the tumor infiltrating lymphocyte
prep was derived from a whole tumor cell suspension where
between 95% and 97% of the cells were negative for the common
lymphocyte antigen CD45, presumably tumor cells, thus providing
a normalization factor. Additionally, tumor sizes were not
significantly larger or smaller 6 days after vaccine treatment,
demonstrating that the absolute number and density of T-cells in
the tumor were greater in the TMEV-L/OVA group.
The presence of tumor invading T-cells in cancer is not an
uncommon occurrence; however mechanisms employed by the
tumor itself help to inhibit further tumor invasion as well as the
specific effector functions of T-cells. Vaccination with TMEV-L/
OVA induces the enhanced infiltration of T-cells into target tissues
and this infiltration was associated with dramatic induction of
diabetes using the RIP-OVA model and also led to an increase in
cytotoxicity of tumor infiltrating lymphocytes with an accompa-
nied decline in tumor outgrowth and increased survival. Although
these were not overt cures of established tumors, the ability to
target specific tumor antigens was apparent as the outgrowth of
tumors in vaccinated mice showed substantial reductions in overall
tumor antigen expression, as well as a decrease in the number of
tumor cells that expressed antibiotic resistance associated with the
ovalbumin transgene introduced into the B16 tumor line. Future
experiments designed to optimize the tumor specific immune
response through modification of the viral genome may increase
this virus’ efficacy in established tumor models.
Several viruses in the picornaviridae family have been studied
for their ability to selectively target, infect and lyse tumor cells
[39,40,41]. However, TMEV-L/OVA vaccines indirectly target
tumor cells by eliciting cytotoxic T-cell immunity that kills tumor
cells with exquisite specificity. Although wild-type TMEV can
infect B16 in vitro (data not shown), no effect on tumor growth was
observed when either wild-type or TMEV-L/OVA virus vaccines
were given to B16 bearing mice. Further, vaccination of B16-OVA
bearing mice with wild-type virus did not alter tumor growth
kinetics, suggesting that TMEV does not promote epitope
spreading to tumor associated antigens. Only the epitope modified
virus, which can specifically induce cytotoxic T-cells that target
tumor associated antigens, had an effect on the outgrowth of
tumors.
Optimal vaccines for immunotherapy must be easily amenable
to modification, must target multiple antigens, and most
Figure 5. Delayed tumor outgrowth using TMEV-L/OVA vaccine in a therapeutic model of established tumor burden. FACS analysis of
6 day BIL (A) and TIL (B) from mice given TMEV vaccines on day 9 after B16-OVA implantation. Lymphocytes were assessed for the presence of
OVA257, VP2121 and E749 specific CD8 T-cell responses. Percentages are the percent of tetramer specific CD8 cells. Numbers represent the absolute
numbers of cells per 100,000 events. (C) Four hour chromium release assay using day 15 TIL from mice treated with TMEV-L/OVA or TMEV-wt 9 days
after B16-OVA challenge. (D) (left) Observed tumor growth in mice treated with TMEV-wt or TMEV-L/OVA. (p,0.05 at day 21 and 24). Tumor
outgrowth and survival of individual animals treated with TMEV vaccines. Significant differences in survival were observed between the treatment
groups at the conclusion of the 30 day observation period (p,0.05).
doi:10.1371/journal.pone.0020217.g005
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PLoS ONE | www.plosone.org 10 May 2011 | Volume 6 | Issue 5 | e20217importantly, must elicit the type of immunity required to eradicate
infectious agents or to eliminate cancer cells. TMEV represents an
attractive new candidate that can be easily manipulated with
standard techniques, yet elicits strong T-cell immunity that can be
harnessed and targeted towards tumor cells. These characteristics
make TMEV an attractive vaccine vector for the induction of
cellular immunity against tumors and may provide a novel vaccine
strategy for targeting tumors that have not responded to existing
chemotherapy and vaccination strategies.
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